TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A case report describes a 50-year-old woman with bipolar disorder whose lithium level rose after she began tirzepatide, alongside tremor, slurred speech and blurred vision. Her symptoms subsided after her lithium dose was reduced, but one case cannot establish that tirzepatide caused the change. A psychiatrist not involved in the report recommends early lithium and kidney-function monitoring when the medicines are started together.
A case report published in the Journal of Clinical Psychopharmacology describes a 50-year-old woman with bipolar disorder whose lithium level rose after she started tirzepatide, followed by tremor, slurred speech and blurred vision. Her symptoms subsided after her lithium dose was reduced, but the report does not prove the medicines caused the change; clinicians say the case supports early monitoring when the drugs are used together.
The woman had been taking lithium 900 mg nightly for bipolar disorder. Before tirzepatide was prescribed, her serum lithium level was 0.7 mmol/L, and tests showed normal kidney function and no electrolyte abnormalities. She began a weekly 2.5 mg dose of tirzepatide, a dual GIP/GLP-1 receptor agonist, for chronic weight management.
About three weeks after starting tirzepatide, she reported two days of new symptoms: tremor in both hands, slurred speech and blurred vision. A trough lithium test the following day measured 1.2 mmol/L. The report says she had not changed her lithium dose or how she took it, and had not started another medication. She did report eating smaller meals, feeling full sooner and experiencing some bloating after beginning tirzepatide.
Her clinicians advised her to reduce lithium to 450 mg nightly. The symptoms soon subsided, and a trough level 17 days later was 0.4 mmol/L. She lost five pounds during three weeks on tirzepatide, but decided with her doctor not to restart it. She was gradually titrated back to 900 mg of lithium nightly. The report authors describe the suspected interaction as probable, while noting that the mechanism is not established.
Monitoring Lithium When Tirzepatide Starts
The report matters because lithium has a relatively narrow range between effective and potentially harmful blood concentrations, and changes in its level can have clinical consequences. The case suggests clinicians may want to pay attention to lithium levels and symptoms when a patient begins tirzepatide, particularly as appetite and food intake change. It does not establish how often this may happen or show that every patient taking both medicines is at risk.
Jorge Almeida, a psychiatrist at the University of Texas at Austin who was not involved in the report, said the practical message is early monitoring, not automatic avoidance. He suggested checking lithium levels and kidney function within the first few weeks after starting an incretin medicine and again after dose changes. Patients should discuss warning signs with their prescriber and should not stop either medicine on their own.
The medicines may both have a role for some people with bipolar disorder, who can also have obesity or type 2 diabetes. The report authors describe lithium as a cornerstone of bipolar disorder management and say incretin medicines may offer benefits for weight and blood sugar. Decisions about using them together require individualized clinical oversight rather than conclusions drawn from one case.
Products Worth Considering
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
OMRON VIVA 360+ Body Composition Monitor and Smart Scale
Withings Body Smart Wi-Fi and Bluetooth Smart Scale
As an affiliate, we earn on qualifying purchases.
How the Suspected Interaction Emerged
The report was written by Jay Davis, MD, of the University of Colorado Anschutz Medical Campus, and colleagues. They said the case is the fourth reported case of tirzepatide-associated lithium toxicity. That count refers to reports, not a measured rate of risk; the available case descriptions do not establish how frequently the interaction occurs.
Davis told MedPage Today that one proposed explanation is that reduced food and fluid intake may increase the fraction of lithium reabsorbed by the kidneys. He said the favored mechanism involves increased fractional reabsorption linked to lower oral intake, while emphasizing that the interaction is still not well understood. In this patient, smaller meals and earlier fullness were reported, but the case cannot show that those changes caused the lithium level to rise.
Almeida, who was not involved, said the timeline and improvement after lithium was reduced make the report difficult to dismiss, while cautioning that a single case cannot prove cause and effect. The case adds to a small, growing set of observations, not controlled evidence comparing outcomes among patients taking these medicines.
“The favored mechanism for this medication interaction – increased fractional reabsorption due to decreased oral intake – raises interesting questions about whether and how these medications might be prescribed safely together.”
— Jay Davis, MD, University of Colorado Anschutz Medical Campus, speaking to MedPage Today
Cause, Frequency and Mechanism Remain Unknown
The case cannot determine whether tirzepatide directly raised the patient’s lithium level, whether reduced intake contributed, or whether another unmeasured factor played a part. It also cannot establish the frequency or size of any risk for people taking the two medicines. The report provides no controlled comparison or population-level estimate.
The proposed effect of changes in eating and drinking is a hypothesis, not a confirmed mechanism. The patient’s kidney function was reported as normal before the event, but that does not resolve how the level changed. It is also unclear whether the same concern applies to other GLP-1 medicines or to all people taking lithium and tirzepatide.
Clinicians Call for Early Follow-Up
Davis and colleagues call for greater awareness and further study of potential interactions as incretin medicines are prescribed to more people who take lithium. Almeida advised checking lithium levels and kidney function within the first few weeks after starting treatment and again following dose changes. These are his clinical recommendations, not findings from a trial establishing a monitoring schedule.
For patients, the report’s experts emphasize contacting the prescribing clinician if new symptoms arise and discussing medication changes with that clinician rather than stopping either drug independently. Further reports and research will be needed to clarify the mechanism, the likelihood of the interaction and how best to manage treatment when both medicines are considered.
Key Questions
What happened in the case report?
A woman taking lithium for bipolar disorder developed tremor, slurred speech and blurred vision about three weeks after starting tirzepatide. Her lithium level was higher than a previous measurement, and her symptoms subsided after her lithium dose was reduced.
Does the report prove tirzepatide caused lithium toxicity?
No. The timing and response to lowering lithium suggest a possible interaction, but one case cannot prove cause and effect or rule out other explanations.
Should people taking lithium avoid tirzepatide?
The report does not establish that everyone taking lithium should avoid tirzepatide. Almeida said the practical message is monitoring rather than automatic avoidance. Patients should discuss their own treatment with their prescriber.
What monitoring did the outside expert suggest?
Almeida suggested checking lithium levels and kidney function within the first few weeks of starting an incretin medicine and again after dose changes. This is expert guidance quoted in the report, not a schedule validated by a clinical trial.
What symptoms were reported in this case?
The patient experienced tremor in both hands, slurred speech and blurred vision. Anyone taking lithium who develops concerning new symptoms should contact their prescriber; the report’s experts advised against stopping either medicine without medical guidance.
Source: medpagetoday.com
